A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.

@article{Glisson2017ARP,
  title={A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.},
  author={Bonnie S. Glisson and Benjamin Besse and Manuel Cobo Dols and Sarita Dubey and Marco Schupp and Rajul K. Jain and Yizhou Jiang and Hari Vinayak Menon and Kristiaan Nackaerts and Sergey V Orlov and Luis Paz-Ares and Rodryg Adam Ramlau and Rui Tang and Yilong Zhang and Min Zhu},
  journal={Clinical lung cancer},
  year={2017},
  volume={18 6},
  pages={
          615-625.e8
        }
}
INTRODUCTION/BACKGROUND In this randomized, double-blind, placebo-controlled phase 1b/2 study we assessed the efficacy/safety of rilotumumab or ganitumab combined with etoposide and carboplatin or cisplatin as first-line treatment in patients with extensive stage small-cell lung cancer (ES-SCLC). PATIENTS AND METHODS In the phase 1b study, patients received rilotumumab 15 mg/kg or ganitumab 18 mg/kg with etoposide and carboplatin or cisplatin. In the phase 2 study, patients were randomly… CONTINUE READING